GeneTether Therapeutics Inc. (GTTX.CN)
| Previous Close | 0.0700 |
| Open | 0.0000 |
| Bid | 0.0300 x N/A |
| Ask | 0.1000 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 4,055 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics
The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics on their latest news.
- ACCESSWIRE
The Power Play by The Market Herald Releases New Interview with GeneTether Therapeutics
VANCOUVER, BC / ACCESSWIRE / May 30, 2022 / The Power Play by The Market Herald has announced the release of a new interview with GeneTether Therapeutics on their latest news.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.
- CNW Group
GeneTether Therapeutics Announces Issuance of New US Composition of Matter Patent for its Innovative Platform Technology Focused on Gene Editing Efficiency
GeneTether Therapeutics Inc., ("GeneTether" or the "Company") (CSE: GTTX) announced today that the United States Patent and Trademark Office has granted patent #11,339,385 entitled "Modified Nucleic Acid Editing Systems for Tethering Donor DNA" related to its GeneTether platform technology. The claims cover a composition of matter for tethering a donor DNA template to a fusion protein of a nuclease and the lac repressor DNA binding domain, in particular where the donor DNA includes the lac opera
